Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
Pfizer Investigational Site, Danville, Virginia, United States
Oregon Health & Science University, Portland, Oregon, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Veterans Administration, Nashville, Tennessee, United States
Department of Chemoradiation, Tehran, Iran, Islamic Republic of
University Hospitals Case Medical Center, Beachwood, Ohio, United States
Boston Medical Center, Boston, Massachusetts, United States
National Cancer Centre - Singapore, Singapore, Singapore
Veteran Affairs (VA) Medical Center, Salt Lake City, Utah, United States
Pfizer Investigational Site, Harrow, Middlesex, England, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.